Clinical trials: Schizophrenia Therapeutics
Psychosis
Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis
Preventing psychotic disorders such as schizophrenia and associated functional disability could relieve an enormous burden of personal and family suffering and economic losses to society.
- Trial name
- NCT01907282
- Testing
- Family Focused Treatment, Enhanced Care
- Where
- 8 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- University of California, Los Angeles
Schizophrenia Prodrome
Ethyl-EPA Treatment of Prodromal Patients
This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.
- Trial name
- NCT00634361
- Testing
- ethyl-eicosapentaenoic acid
- Volunteers
- 7 people
- Sponsor
- Yale University
Schizophrenia, Negative Symptoms in Schizophrenia
Dance and Movement Therapy in Patients With Schizophrenia
Introduction: Schizophrenia is a mental disorder that starts at a young age and progresses with positive (hallucination, delusion) and negative (decreased emotional participation, reluctance) symptoms.
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia, Disabilities Mental, Dance Therapy
- Trial name
- DMTinSchizo (NCT05500651)
- Testing
- Dance and Movement Therapy (DMT)
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Amasya University
Schizophrenia
Anti-inflammatories and Adolescent Schizophrenia
A double-blind controlled trial assessing the efficacy of anti-inflammatories on symptoms and cognition of adolescents with schizophrenia
- Trial name
- NCT04020588
- Testing
- Celecoxib 200mg, Minocycline 100mg
- Where
- Mexico
- Volunteers
- 90 people
- Sponsor
- Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
Psychosis, Clinical High Risk for Psychosis
Using Mobile Technology to Enhance Early Psychosis Treatment Delivery
This project tests the feasibility of implementing a smartphone application - Ginger.io - in the UC Davis Early Psychosis Program, and investigates whether mobile health technology can improve treatment delivery and outcomes in…
- Trial name
- RWJFGinger (NCT03303456)
- Testing
- Mobile health application - Ginger.io
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Prodromal Schizophrenia
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
The Ohio State University Early Psychosis Intervention Center is implementing a specialized clinical program to serve individuals who meet clinical high risk criteria for a psychosis.
- Trial name
- NCT03970005
- Testing
- Step-Based Care Model
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ohio State University
Schizophrenia
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events.
- Trial name
- SHINE (NCT03893825)
- Testing
- TV-46000
- Where
- 90 sites in United States, Bulgaria and 3 more
- Volunteers
- 336 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia Patients, Psychoeducation
The Effect of Psychosocial Skills Focused Group Psychoeducation in Schizophrenia Patients
The aim of this study was to evaluate the effect of psychosocial skills-oriented group psychoeducation on functional recovery, treatment adherence and mental well-being in patients with schizophrenia.
- Conditions
- Schizophrenia Patients, Psychoeducation, Functional Status, Treatment Outcome
- Trial name
- Schizophrenia (NCT06872424)
- Testing
- psychosocial skills-oriented group psychoeducation
- Volunteers
- 34 people
- Sponsor
- Gazi University
Schizophrenia, Psychosis
Aripiprazole Treatment of Prodromal Patients
We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.
- Trial name
- NCT00237874
- Testing
- Aripiprazole
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Yale University
Schizophrenia, Bipolar Disorder
Integrated Care Including Assertive Community Treatment in Early Psychosis
Improvement of clinical long-term outcome through the implementation of early detection and intervention within a specialized network of integrated care (ACT and hometreatment) for adolescents and young adults with a first…
- Trial name
- ICEP (NCT02037581)
- Testing
- Early detection and Integrated Care, Standard Care
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
It's a prospective, non-interventional, observational Post-marketing Surveillance..
- Trial name
- NCT04432688
- Testing
- Lurasidone HCl
- Where
- 7 sites in China
- Volunteers
- 3,192 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia, Bipolar Disorder
Longitudinal Effect of Electroconvulsive Therapy on Schizophrenia and Bipolar Disorder: a MRI Study
For more severe and treatment-resistant cases in schizophrenia and bipolar disorder, electroconvulsive therapy (ECT) is often very effective.
- Trial name
- NCT03651674
- Testing
- ECT treatment, Drug treatment
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Xidian University
Psychotic Disorders
Implementation of National Guidelines for Treatment of Psychoses
The study is a combined health services research study and a clinical patient outcomes sub-study. The aims of the study are to give new knowledge on (RQ1) current implementation in mental health services of four evidence based…
- Trial name
- NCT03271242
- Testing
- Systematic implementation support, No implementation support
- Volunteers
- 325 people
- Sponsor
- University Hospital, Akershus
Schizophrenia, Schizophreniform Disorder
DECIFER: Depression and Citalopram In First Episode Recovery
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients.
- Trial name
- DECIFER (NCT01041274)
- Testing
- Citalopram, Psychoeducation, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Diabetes, Hypertension
Pharmacy Interventions to Improve Chronic Disease Medication Refill
Compare the effectiveness of 3 strategies by pharmacists to decrease the time to refill of prescriptions for common chronic diseases (diabetes, hypertension, hyperlipidemia, heart failure, depression, psychoses).
- Conditions
- Diabetes, Hypertension, Hyperlipidemia, Heart Diseases
- Trial name
- NCT00469365
- Testing
- pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care
- Where
- United States
- Volunteers
- 3,048 people
- Sponsor
- Medical University of South Carolina
Mental Disorder in Adolescence, Bipolar Disorder
Investigation of the Effects of Family-Focused Therapy in the Early Period of Bipolar Disorder and Psychotic Disorder
Family-focused therapy (FFT) is a comprehensive therapy approach applied to individuals and their families. In the present study, the researchers aimed to investigate the effects of family-focused therapy (FFT) in the early…
- Conditions
- Mental Disorder in Adolescence, Bipolar Disorder, Psychosis, Family Relations
- Trial name
- NCT05809193
- Testing
- Family-Focused Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Dokuz Eylul University
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Bipolar Disorder, Affective Disorders, Psychotic
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.
- Conditions
- Bipolar Disorder, Affective Disorders, Psychotic, Mood Disorders, Mental Disorders
- Trial name
- NCT00035802
- Testing
- Topiramate
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.